Machado Joseph disease: clinical and genetic aspects, and current treatment

Bibliography

• KKNakano, DMDawson, ASpence. Machado disease. A hereditary ataxia in Portuguese emigrants to Massachusetts. Neurology 1972;22:49-55
   PubMed Web of Science ®Google Scholar
• BTWoods, HHSchaumburg. Nigro-spino-dentatal degeneration with nuclear ophthalmoplegia. A unique and partially treatable clinico-pathological entity. J Neurol Sci 1972;17:149-66
   PubMed Web of Science ®Google Scholar
• RNRosenberg, WLNyhan, CBay, PShore. Autosomal dominant striatonigral degeneration. A clinical, pathologic, and biochemical study of a new genetic disorder. Neurology 1976;26:703-14
   PubMed Web of Science ®Google Scholar
• YTakiyama, MNishizawa, HTanaka, et al. The gene for Machado-Joseph disease maps to human chromosome 14q. Nat Genet 1993;4:300-4
   Google Scholar
• YKawaguchi, TOkamoto, MTaniwaki, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994;8:221-8
   PubMed Web of Science ®Google Scholar
• JSequeiros, SMartins, ISilveira. Epidemiology and population genetics of degenerative ataxias. Handb Clin Neurol 2012;103:227-51
   Google Scholar
• RMde Castilhos, GVFurtado, TCGheno, et al. Spinocerebellar ataxias in Brazil – frequencies and modulating effects of related genes. Cerebellum 2014;13:17-28
   Google Scholar
• PCoutinho, LRuano, JLLoureiro, et al. Hereditary ataxia and spastic paraplegia in Portugal: a population-based prevalence study. JAMA Neurol 2013;70:746-55
   PubMed Web of Science ®Google Scholar
• PRPrestes, MLSaraiva-Pereira, ISilveira, et al. Machado-Joseph disease enhances genetic fitness: a comparison between affected and unaffected women and between MJD and the general population. Ann Hum Genet 2008;72:57-64
   Google Scholar
• SMartins, B-WSoong, VCNWong, et al. Mutational origin of Machado-Joseph disease in the Australian Aboriginal communities of Groote Eylandt and Yirrkala. Arch Neurol 2012;69:746-51
   Google Scholar
• CCosta M do, HLPaulson. Toward understanding Machado-Joseph disease. Prog Neurobiol 2012;97:239-57
   Google Scholar
• ISchmitt, MLinden, HKhazneh, et al. Inactivation of the mouse Atxn3 (ataxin-3) gene increases protein ubiquitination. Biochem Biophys Res Commun 2007;362:734-9
   PubMed Web of Science ®Google Scholar
• SAlves, INascimento-Ferreira, et al. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3? Hum Mol Genet 2010;19:2380-94
   PubMed Web of Science ®Google Scholar
• GSobue, MDoyu, NNakao, et al. Homozygosity for Machado-Joseph disease gene enhances phenotypic severity. J Neurol Neurosurg Psychiatry 1996;60:354-6
   Google Scholar
• ILerer, DMerims, DAbeliovich, et al. Machado-Joseph disease: correlation between the clinical features, the CAG repeat length and homozygosity for the mutation. Eur J Hum Genet 1996;4:3-7
   PubMed Web of Science ®Google Scholar
• TFukutake, HShinotoh, HNishino, et al. Homozygous Machado-Joseph disease presenting as REM sleep behaviour disorder and prominent psychiatric symptoms. Eur J Neurol 2002;9:97-100
   Google Scholar
• CRGordon, VJoffe, GVainstein, NGadoth. Vestibulo-ocular arreflexia in families with spinocerebellar ataxia type 3 (Machado-Joseph disease). J Neurol Neurosurg Psychiatry 2003;74:1403-6
   PubMed Web of Science ®Google Scholar
• LLysenko, RPGrewal, WMa, LRPeddareddygari. Homozygous Machado Joseph Disease: a case report and review of literature. Can J Neurol Sci 2010;37:521-3
   Google Scholar
• PMaciel, MCCosta, AFerro, et al. Improvement in the molecular diagnosis of Machado-Joseph disease. Arch Neurol 2001;58:1821-7
   PubMedGoogle Scholar
• DRCarvalho, ALa Rocque-Ferreira, IMRizzo, et al. Homozygosity enhances severity in spinocerebellar ataxia type 3. Pediatr Neurol 2008;38:296-9
   Google Scholar
• LBJardim, MLPereira, ISilveira, et al. Machado-Joseph disease in South Brazil: clinical and molecular characterization of kindreds. Acta Neurol Scand 2001;104:224-31
   Google Scholar
• HSasaki, AWakisaka, TFukazawa, et al. CAG repeat expansion of Machado-Joseph disease in the Japanese: analysis of the repeat instability for parental transmission, and correlation with disease phenotype. J Neurol Sci 1995;133:128-33
   Google Scholar
• ADürr, GStevanin, GCancel, et al. Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features. Ann Neurol 1996;39:490-9
   PubMed Web of Science ®Google Scholar
• WGu, HMa, KWang, et al. The shortest expanded allele of the MJD1 gene in a Chinese MJD kindred with autonomic dysfunction. Eur Neurol 2004;52:107-11
   Google Scholar
• SMartins, PCoutinho, ISilveira, et al. Cis-acting factors promoting the CAG intergenerational instability in Machado-Joseph disease. Am J Med Genet B Neuropsychiatr Genet 2008;147:439-46
   Google Scholar
• ILopes-Cendes, PMaciel, et al. Somatic mosaicism in the central nervous system in spinocerebellar ataxia type 1 and Machado-Joseph disease. Ann Neurol 1996;40:199-206
   Google Scholar
• PMaciel, CGaspar, ALDeStefano, et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. Am J Hum Genet 1995;57:54-61
   PubMed Web of Science ®Google Scholar
• PIughetti, PAOtto, MZatz, et al. Different behavior in the paternally vs. maternally inherited mutated allele in Brazilian Machado-Joseph (MJD1) families. Am J Med Genet 1998;77:246-8
   Google Scholar
• YTakiyama, KSakoe, MSoutome, et al. Single sperm analysis of the CAG repeats in the gene for Machado-Joseph disease (MJD1): evidence for non-Mendelian transmission of the MJD1 gene and for the effect of the intragenic CGG/GGG polymorphism on the intergenerational instability. Hum Mol Genet 1997;6:1063-8
   Google Scholar
• MFrontali, GSabbadini, ANovelletto, et al. Genetic fitness in Huntington’s Disease and Spinocerebellar Ataxia 1: a population genetics model for CAG repeat expansions. Ann Hum Genet 1996;60:423-35
   Google Scholar
• LBJardim, MLPereira, ISilveira, et al. Neurologic findings in Machado-Joseph disease: relation with disease duration, subtypes, and (CAG)n. Arch Neurol 2001;58:899-904
   PubMedGoogle Scholar
• MCFrança, AD’Abreu, ANucci, et al. Progression of ataxia in patients with Machado-Joseph disease. Mov Disord 2009;24:1387-90
   PubMed Web of Science ®Google Scholar
• LBJardim, LHauser, CKieling, et al. Progression rate of neurological deficits in a 10-year cohort of SCA3 patients. Cerebellum 2010;9:419-28
   PubMed Web of Science ®Google Scholar
• HJacobi, PBauer, PGiunti, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 2011;77:1035-41
   PubMed Web of Science ®Google Scholar
• KReetz, ASCosta, SMirzazade, et al. Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain 2013;136:905-17
   PubMed Web of Science ®Google Scholar
• CKieling, PRPrestes, MLSaraiva-Pereira, LBJardim. Survival estimates for patients with Machado-Joseph disease (SCA3). Clin Genet 2007;72:543-5
   Google Scholar
• URüb, LSchöls, HPaulson, et al. Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Prog Neurobiol 2013;104:38-66
   PubMed Web of Science ®Google Scholar
• PCoutinho, CAndrade. Autosomal dominant system degeneration in Portuguese families of the Azores Islands. A new genetic disorder involving cerebellar, pyramidal, extrapyramidal and spinal cord motor functions. Neurology 1978;28:703-9
   PubMed Web of Science ®Google Scholar
• TSchmitz-Hübsch, MCoudert, PBauer, et al. Spinocerebellar ataxia types 1, 2, 3, and 6: disease severity and nonataxia symptoms. Neurology 2008;71:982-9
   PubMed Web of Science ®Google Scholar
• PTrouillas, TTakayanagi, MHallett, et al. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J Neurol Sci 1997;145:205-11
   PubMed Web of Science ®Google Scholar
• TSchmitz-Hübsch, RFimmers, MRakowicz, et al. Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology 2010;74:678-84
   PubMed Web of Science ®Google Scholar
• CKieling, CRMRieder, ACFSilva, et al. A neurological examination score for the assessment of spinocerebellar ataxia 3 (SCA3). Eur J Neurol 2008;15:371-6
   PubMed Web of Science ®Google Scholar
• SCamey, LBJardim, CKieling, et al. A prospective study of SCA3 gait ataxia described through a Markovian method. Neuroepidemiology 2010;34:163-70
   Google Scholar
• HJacobi, KReetz, STdu Montcel, et al. Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3 and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol 2013;12:650-8
   PubMed Web of Science ®Google Scholar
• JASaute, KCDonis, CSerrano-Munuera, et al. Ataxia rating scales--psychometric profiles, natural history and their application in clinical trials. Cerebellum 2012;11:488-504
   PubMed Web of Science ®Google Scholar
• LJardim, ISilveira, MLPereira, et al. Searching for modulating effects of SCA2, SCA6 and DRPLA CAG tracts on the Machado-Joseph disease (SCA3) phenotype. Acta Neurol Scand 2003;107:211-14
   PubMed Web of Science ®Google Scholar
• STezenas du Montcel, ADurr, PBauer, et al. Modulation of the age at onset in spinocerebellar ataxia by CAG tracts in various genes. Brain 2014;137:2444-55
   PubMed Web of Science ®Google Scholar
• CBettencourt, MRaposo, NKazachkova, et al. The APOE epsilon2 allele increases the risk of earlier age at onset in Machado-Joseph disease. Arch Neurol 2011;68:1580-3
   Google Scholar
• MSiebert, KCDonis, MSocal, et al. Glucocerebrosidase gene variants in parkinsonian patients with Machado Joseph/spinocerebellar ataxia 3. Parkinsonism Relat Disord 2012;18:185-90
   Google Scholar
• VEEmmel, IAlonso, LBJardim, et al. Does DNA methylation in the promoter region of the ATXN3 gene modify age at onset in MJD (SCA3) patients? Clin Genet 2011;79:100-2
   Google Scholar
• TSchmitz-Hübsch, MCoudert, STezenas du Montcel, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord 2011;26:870-6
   PubMed Web of Science ®Google Scholar
• JLPedroso, MCFrança, PBraga-Neto, et al. Nonmotor and extracerebellar features in Machado-Joseph disease: a review. Mov Disord 2013;28:1200-8
   PubMed Web of Science ®Google Scholar
• HLPaulson, SSDas, PBCrino, et al. Machado-Joseph disease gene product is a cytoplasmic protein widely expressed in brain. Ann Neurol 1997;41:453-62
   PubMed Web of Science ®Google Scholar
• TSchmidt, GBLandwehrmeyer, ISchmitt, et al. An isoform of ataxin-3 accumulates in the nucleus of neuronal cells in affected brain regions of SCA3 patients. Brain Pathol 1998;8(4):669-79
   PubMed Web of Science ®Google Scholar
• URüb, ERBrunt, TDeller. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado-Joseph disease). Curr Opin Neurol 2008;21:111-16
   PubMed Web of Science ®Google Scholar
• KSeidel, WFAden Dunnen, CSchultz, et al. Axonal inclusions in spinocerebellar ataxia type 3. Acta Neuropathol 2010;120:449-60
   Google Scholar
• KSeidel, MMeister, GJDugbartey, et al. Cellular protein quality control and the evolution of aggregates in spinocerebellar ataxia type 3 (SCA3). Neuropathol Appl Neurobiol 2012;38:548-58
   Google Scholar
• CJCummings, EReinstein, YSun, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999;24:879-92
   PubMed Web of Science ®Google Scholar
• YNagai, TInui, HAPopiel, et al. A toxic monomeric conformer of the polyglutamine protein. Nat Struct Mol Biol 2007;14:332-40
   PubMed Web of Science ®Google Scholar
• UBichelmeier, TSchmidt, JHübener, et al. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence. J Neurosci 2007;27:7418-28
   PubMed Web of Science ®Google Scholar
• A-HChou, T-HYeh, POuyang, et al. Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation. Neurobiol Dis 2008;31:89-101
   Google Scholar
• JSequeiros, SSeneca, JMartindale. Consensus and controversies in best practices for molecular genetic testing of spinocerebellar ataxias. Eur J Hum Genet 2010;18:1188-95
   PubMed Web of Science ®Google Scholar
• BPCVan de Warrenburg, Jvan Gaalen, SBoesch, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol 2014;21:552-62
   PubMed Web of Science ®Google Scholar
• DCWertz, GFFletcher, KBerg. Programme WHG. Review of ethical issues in medical genetics: report of consultants to WHO. World Health Organization. 2003
   Google Scholar
• LSchuler-Faccini, CMOsorio, FRomariz, et al. Genetic counseling and presymptomatic testing programs for Machado-Joseph disease: lessons from Brazil and Portugal. Genet Mol Biol 2014;37:263-70
   PubMed Web of Science ®Google Scholar
• VFColomer Gould. Mouse models of spinocerebellar ataxia type 3 (Machado-Joseph disease). Neurotherapeutics 2012;9(2):285-96
   Google Scholar
• MCorreia, PCoutinho, MCSilva, et al. Evaluation of the effect of sulphametoxazole and trimethoprim in patients with Machado-Joseph disease. Rev Neurol 1995;23:632-4
   Google Scholar
• TSakai, TMatsuishi, SYamada, et al. Sulfamethoxazole-trimethoprim double-blind, placebo-controlled, crossover trial in Machado-Joseph disease: sulfamethoxazole-trimethoprim increases cerebrospinal fluid level of biopterin. J Neural Transm Gen Sect 1995;102:159-72
   Google Scholar
• TSchulte, RMattern, KBerger, et al. Double-blind crossover trial of trimethoprim-sulfamethoxazole in spinocerebellar ataxia type 3/Machado-Joseph disease. Arch Neurol 2001;58:1451-7
   Google Scholar
• KWessel, KLangenberger, MFNitschke, DKömpf. Double-blind crossover study with physostigmine in patients with degenerative cerebellar diseases. Arch Neurol 1997;54:397-400
   Google Scholar
• TLMonte, CRMRieder, ABTort, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand 2003;107:207-10
   PubMed Web of Science ®Google Scholar
• ATakei, SHamada, SHomma, et al. Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum 2010;9:567-70
   PubMed Web of Science ®Google Scholar
• C-SLiu, H-MHsu, W-LCheng, MHsieh. Clinical and molecular events in patients with Machado-Joseph disease under lamotrigine therapy. Acta Neurol Scand 2005;111:385-90
   PubMed Web of Science ®Google Scholar
• MAssadi, JVCampellone, CGJanson, et al. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci 2007;260:143-6
   PubMed Web of Science ®Google Scholar
• JArpa, ISanz-Gallego, JMedina-Báez, et al. Subcutaneous insulin-like growth factor-1 treatment in spinocerebellar ataxias: an open label clinical trial. Mov Disord 2011;26:358-9
   Google Scholar
• STdu Montcel, PCharles, PRibai, et al. Composite cerebellar functional severity score: validation of a quantitative score of cerebellar impairment. Brain 2008;131:1352-61
   PubMed Web of Science ®Google Scholar
• TSchmitz-Hübsch, PGiunti, DAStephenson, et al. SCA Functional Index: a useful compound performance measure for spinocerebellar ataxia. Neurology 2008;71:486-92
   PubMed Web of Science ®Google Scholar
• IGiordano, MBogdanow, HJacobi, et al. Experience in a short-term trial with 4-aminopyridine in cerebellar ataxia. J Neurol 2013;260:2175-6
   Google Scholar
• JASaute, RMde Castilhos, TLMonte, et al. A randomized, phase 2 clinical trial of lithium carbonate in Machado-Joseph disease. Mov Disord 2014;29:568-73
   PubMed Web of Science ®Google Scholar
• EChan, PCharles, PRibai, et al. Quantitative assessment of the evolution of cerebellar signs in spinocerebellar ataxias. Mov Disord 2011;26:534-8
   PubMed Web of Science ®Google Scholar
• JBoy, TSchmidt, HWolburg, et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet 2009;18:4282-95
   PubMed Web of Science ®Google Scholar
• AMatilla-Dueñas, TAshizawa, ABrice, et al. Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum 2014;13:269-302
   PubMed Web of Science ®Google Scholar
• JASaute, ACFda Silva, APMuller, et al. Serum insulin-like system alterations in patients with spinocerebellar ataxia type 3. Mov Disord 2011;26:731-5
   Google Scholar
• MPZijlstra, MARujano, MAVan Waarde, et al. Levels of DNAJB family members (HSP40) correlate with disease onset in patients with spinocerebellar ataxia type 3. Eur J Neurosci 2010;32:760-70
   Google Scholar
• ABLTort, LVPortela, ICRockenbach, et al. S100B and NSE serum concentrations in Machado Joseph disease. Clin Chim Acta 2005;351:143-8
   Google Scholar
• JZhou, LLei, YShi, et al. Serum concentrations of NSE and S100B in spinocerebellar ataxia type 3/Machado-Joseph disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011;36:504-10
   Google Scholar
• YShi, FHuang, BTang, et al. MicroRNA profiling in the serums of SCA3/MJD patients. Int J Neurosci 2014;124:97-101
   Web of Science ®Google Scholar
• Adityanjee KRMunshi, AThampy. The syndrome of irreversible lithium-effectuated neurotoxicity. Clin Neuropharmacol 2005;28:38-49
   PubMed Web of Science ®Google Scholar
• FSaccà, GPuorro, ABrunetti, et al. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2. J Neurol 2015;262(1):149-53
   PubMed Web of Science ®Google Scholar
• W-ZYang, YZhang, FWu, et al. Human umbilical cord blood-derived mononuclear cell transplantation: case series of 30 subjects with Hereditary Ataxia. J Transl Med 2011;9:65
   Google Scholar
• J-LJin, ZLiu, Z-JLu, et al. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Curr Neurovasc Res 2013;10:11-20
   PubMed Web of Science ®Google Scholar
• TAZesiewicz, PEGreenstein, KLSullivan, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;78:545-50
   PubMed Web of Science ®Google Scholar
• BSConnolly, LKPrashanth, BBShah, et al. A randomized trial of varenicline (chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012;79:2218
   Google Scholar
• GRistori, SRomano, AVisconti, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010;74:839-45
   PubMed Web of Science ®Google Scholar
• EMFonteyn, SHKeus, CCVerstappen, BPvan de Warrenburg. Physiotherapy in degenerative cerebellar ataxias: utilisation, patient satisfaction, and professional expertise. Cerebellum 2013;12:841-7
   PubMed Web of Science ®Google Scholar
• WIlg, MSynofzik, DBrötz, et al. Intensive coordinative training improves motor performance in degenerative cerebellar disease. Neurology 2009;73:1823-30
   PubMed Web of Science ®Google Scholar
• EMFonteyn, AHeeren, JEngels, et al. Gait adaptability training improves obstacle avoidance and dynamic stability in patients with cerebellar degeneration. Gait Posture 2014;40:247-51
   Google Scholar
• IMiyai, MIto, NHattori, et al. Cerebellar ataxia rehabilitation trial in degenerative cerebellar diseases. Neurorehabil Neural Repair 2012;26:515-22
   PubMed Web of Science ®Google Scholar
• WFreeman, ZWszolek. Botulinum toxin type A for treatment of spasticity in spinocerebellar ataxia type 3 (Machado-Joseph disease). Mov Disord 2005;20:644
   PubMed Web of Science ®Google Scholar
• FCardoso, JTde Oliveira, MPuccioni-Sohler, et al. Eyelid dystonia in Machado-Joseph disease. Mov Disord 2000;15:1028-30
   Google Scholar
• PJTuite, AELang. Severe and prolonged dysphagia complicating botulinum toxin A injections for dystonia in Machado-Joseph disease. Neurology 1996;46:846
   PubMed Web of Science ®Google Scholar
• EWilder-Smith, EKTan, HYLaw, et al. Spinocerebellar ataxia type 3 presenting as an L-DOPA responsive dystonia phenotype in a Chinese family. J Neurol Sci 2003;213:25-8
   PubMed Web of Science ®Google Scholar
• RNandagopal, SGKMoorthy. Dramatic levodopa responsiveness of dystonia in a sporadic case of spinocerebellar ataxia type 3. Postgrad Med J 2004;80:363-5
   PubMed Web of Science ®Google Scholar
• MNunes, AMartinez, ILopes-Cendes, et al. Dystonia in Machado-Joseph disease: clinical features and levodopa response (P6.051). Neurology 2014;82(10 Suppl):P6.051-1
   Google Scholar
• CBuhmann, ABussopulos, MOechsner. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord 2003;18:219-21
   PubMed Web of Science ®Google Scholar
• C-SLu, H-CChang, P-CKuo, et al. The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family. Parkinsonism Relat Disord 2004;10:369-73
   PubMed Web of Science ®Google Scholar
• APVogel, JFolker, MLPoole. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes. Cochrane Database Syst Rev 2014;10:CD008953
   Google Scholar
• RCSilva, JASaute, ACSilva, et al. Occupational therapy in spinocerebellar ataxia type 3: an open-label trial. Braz J Med Biol Res 2010;43:537-42
   Google Scholar
• MCFrança, AD’Abreu, ANucci, ILopes-Cendes. Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 2008;65:525-9
   PubMedGoogle Scholar
• KKanai, SKuwabara, KArai, et al. Muscle cramp in Machado-Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain 2003;126:965-73
   PubMedGoogle Scholar
• MCFrança, AD’Abreu, JHFriedman, et al. Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol 2007;64:1767-70
   PubMedGoogle Scholar
• ATakei, MOkawa, HSasaki, et al. [Effective melatonin therapy in a case of Machado-Joseph disease with insomnia]. Rinsho Shinkeigaku 2000;40:736-40
   Google Scholar
• JLópez-Bastida, LPerestelo-Pérez, FMontón-Alvarez, PSerrano-Aguilar. Social economic costs and health-related quality of life in patients with degenerative cerebellar ataxia in Spain. Mov Disord 2008;23:212-17
   PubMedGoogle Scholar
• HPNguyen, JHübener, JJWeber, et al. Cerebellar soluble mutant ataxin-3 level decreases during disease progression in Spinocerebellar Ataxia Type 3 mice. PLoS One 2013;8:e62043
   Google Scholar
• SAlves, INascimento-Ferreira, GAuregan, et al. Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 2008;3:e3341
   PubMed Web of Science ®Google Scholar
• ERodríguez-Lebrón, CCosta Mdo, KLuna-Cancalon, et al. Silencing mutant ATXN3 expression resolves molecular phenotypes in SCA3 transgenic mice. Mol Ther 2013;21:1909-18
   PubMed Web of Science ®Google Scholar
• MMEvers, H-DTran, IZalachoras, et al. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon. Neurobiol Dis 2013;58:49-56
   PubMed Web of Science ®Google Scholar
• TCoelho, DAdams, ASilva, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819-29
   PubMed Web of Science ®Google Scholar
• TMMiller, APestronk, WDavid, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435-42
   PubMed Web of Science ®Google Scholar
• LSMendonça, CNóbrega, HHirai, et al. Transplantation of cerebellar neural stem cells improves motor coordination and neuropathology in Machado-Joseph disease mice. Brain 2015;138(Pt 2):320-35
   Google Scholar
• TSakai, HKawakami. Machado-Joseph disease: a proposal of spastic paraplegic subtype. Neurology 1996;46:846-7
   Google Scholar
• PJTuite, EARogaeva, PHSt George-Hyslop, AELang. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol 1995;38:684-7
   PubMed Web of Science ®Google Scholar
• INVan Schaik, GJJöbsis, MVermeulen, et al. Machado-Joseph disease presenting as severe asymmetric proximal neuropathy. J Neurol Neurosurg Psychiatry 1997;63(4):534-6
   Google Scholar
• LSchöls, JHaan, ORiess, et al. Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome? Neurology 1998;51:1603-7
   Google Scholar
• AD’Abreu, MFrança, LConz, et al. Sleep symptoms and their clinical correlates in Machado-Joseph disease. Acta Neurol Scand 2009;119:277-80
   Google Scholar
• JLPedroso, PBraga-Neto, ACFelício, et al. Sleep disorders in machado-joseph disease: frequency, discriminative thresholds, predictive values, and correlation with ataxia-related motor and non-motor features. Cerebellum 2011;10:291-5
   PubMed Web of Science ®Google Scholar
• PBraga-Neto, ACFelicio, MQHoexter, et al. Cognitive and olfactory deficits in Machado-Joseph disease: a dopamine transporter study. Parkinsonism Relat Disord 2012;18:854-8
   Google Scholar
• JASaute, ACda Silva, KCDonis, et al. Depressive mood is associated with ataxic and non-ataxic neurological dysfunction in SCA3 patients. Cerebellum 2010;9:603-5
   Google Scholar
• EBrusse, MGBrusse-Keizer, HJDuivenvoorden, JCvan Swieten. Fatigue in spinocerebellar ataxia: patient self-assessment of an early and disabling symptom. Neurology 2011;76:953-9
   PubMed Web of Science ®Google Scholar
• JASaute, ACSilva, GNSouza, et al. Body mass index is inversely correlated with the expanded CAG repeat length in SCA3/MJD patients. Cerebellum 2012;11:771-4; Erratum in: Cerebellum. 2012;11(3):775-6
   PubMed Web of Science ®Google Scholar
• TJDe Rezende, AD’Abreu, RPGuimarães, et al. Cerebral cortex involvement in Machado-Joseph disease. Eur J Neurol 2015;22(2):277-83
   Google Scholar
• RPGuimarães, AD’Abreu, CLYasuda, et al. A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. Mov Disord 2013;28:1125-32
   PubMed Web of Science ®Google Scholar
• CNFahl, LMBranco, FPBergo, et al. Spinal cord damage in Machado-Joseph Disease. Cerebellum 2015;14(2):128-32
   Google Scholar
• J-FLirng, P-SWang, H-CChen, et al. Differences between spinocerebellar ataxias and multiple system atrophy-cerebellar type on proton magnetic resonance spectroscopy. PLoS One 2012;7:e47925
   PubMed Web of Science ®Google Scholar
• LLei, YLiao, WLiao, et al. Magnetic resonance spectroscopy of the cerebellum in patients with spinocerebellar ataxia type 3/Machado-Joseph disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2011;36:511-19
   Google Scholar
• AD’Abreu, MCFrança, CLYasuda, et al. Neocortical atrophy in Machado-Joseph disease: a longitudinal neuroimaging study. J Neuroimaging 2012;22:285-91
   PubMed Web of Science ®Google Scholar
• GÖz, EKittelson, DDemirgöz, et al. Assessing recovery from neurodegeneration in spinocerebellar ataxia 1: comparison of in vivo magnetic resonance spectroscopy with motor testing, gene expression and histology. Neurobiol Dis 2014;74:158-66
   Google Scholar
• UWüllner, MReimold, MAbele, et al. Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch Neurol 2005;62(8):1280-5
   Google Scholar
• MC França, AD’abreu, ANucci, et al. Prospective study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve 2009;40:1012-18
   Google Scholar
• ARLa Spada, EMWilson, DBLubahn, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991;352:77-9
   PubMed Web of Science ®Google Scholar
• HIkeda, MYamaguchi, SSugai, et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996;13:196-202
   PubMed Web of Science ®Google Scholar